,
Erik Vollebregt
I know, nobody likes reminders. But this one is for a good cause: our free seminar / webinar about M&A in the medical devices sector this Wednesday 13 April in the afternoon. …
,
Erik Vollebregt
Today I attended the NEN (Nederlands Normalisatie instituut (Dutch Standardisation Institute)) meeting about “Software and the MDD”, where I presented about recent developments in software and the MDD (apologies to the English…
,
Erik Vollebregt
Traditionally the borderlines between different categories of regulated products (medicinal products, medical devices, food, cosmetics, etc.) have been looked at as strict lines. More and more however it becomes evident that although…
,
Erik Vollebregt
The European Commisison has opened a consultation on 28 March on the revision of the Transparency Directive, the EU directive that regulates certain formalities with regard to reimbursement of medicinal products in…
,
Erik Vollebregt
The DIA Euromeeting in Geneva was an excellent opportunity to meet a number of the regulators involved in the process of the Recast of the EU medical devices directives. Since a lot…
,
Erik Vollebregt
Advertising and promotion of medical devices are not harmonised under the EU medical devices directive, resulting in a fragmented legal landscape that differs from one EU member state to the other. To…
,
Erik Vollebregt
Today the Court of Justice of the EU delivered its much awaited opinion about the compatibility of the envisaged European and EU patent court with the EU treaties, as requested by the…
,
Erik Vollebregt
Some time ago I wrote about issues often overlooked in medical devices M&A transactions. Because of the reactions to it I decided to organise a seminar at my law firm’s Amsterdam office…
,
Erik Vollebregt
On Tuesday 22 February I delivered this presentation at the Q1 2nd Annual European Medical Devices Reimbursement Conference. My presentation addressed the question of what constraints there are on companies providing information…